Adherium

Adherium Share Buybacks

The Share Buybacks of Adherium (ADR.AX) as of Oct 30, 2026 is -641,990.00 AUD. In the previous year, Share Buybacks was -744,000.00 AUD — a change of -13.71% (higher).

Share Buybacks

-641,990.00AUD

YoY

-13.71%

Last updated:

Share Buybacks of Adherium is 2024 -641,990.00 AUD. Share Buybacks of Adherium was 2023 -744,000.00 AUD. It decreases by -13.71% higher compared to the previous year.

The Adherium Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2017
-412,634.97 AUD
Jan 1, 2018
57,332.84 AUD
Jan 1, 2019
0.00 AUD
Jan 1, 2020
-84,788.01 AUD
Jan 1, 2021
-781,664.67 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2023
-744,000.00 AUD
Jan 1, 2024
-641,990.00 AUD
The Adherium Share Buybacks history
YEARShare BuybacksYoY
-641,990.00AUD-13.71%
-744,000.00AUD—
0.00AUD-100.00%
-781,664.67AUD+821.90%
-84,788.01AUD—
0.00AUD-100.00%
57,332.84AUD-113.89%
-412,634.97AUD-101.44%
28.61 MAUD+147,508.33%
19,380.12AUD-80.84%
101,167.44AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adherium Stock analysis

What does Adherium do? Adherium Ltd develops and supplies connected medical devices and respiratory medications for patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company generates revenue through its Hailie sensor technology and cloud-based data platform, which provides real-time feedback on patients' use of inhaled medication. The Hailie Remote Patient Management (RPM) Solution, Hailie Sensors, and Hailie Solution are key products sold to healthcare providers, payers, and pharmaceutical companies. These solutions enable optimal management of severe asthma and COPD, reduce healthcare costs, and offer remote monitoring capabilities for patients and physicians. The Hailie Sensor technology wraps around inhalers and connects via Bluetooth to capture medication use data, which is transmitted to the cloud-based Hailie platform. This platform delivers real-time feedback to patients through the Hailie app and to physicians via the Hailie portal. The company's focus on patient medication adherence and remote monitoring drives demand from healthcare providers seeking to improve treatment outcomes and from pharmaceutical companies aiming to enhance patient engagement with their respiratory medications. Adherium's products target segments including patients with severe asthma and COPD, healthcare providers managing chronic conditions, payers interested in cost reduction, and pharmaceutical companies developing respiratory medications. The company's revenue model centers on selling its sensor technology, cloud platform access, and integrated RPM solutions to these key segments, leveraging FDA-cleared devices to ensure compliance and reliability in healthcare settings. Adherium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adherium stock

Share Buybacks of Adherium is -641,990.00 AUD in 2024.

Share Buybacks of Adherium changed from -744,000.00 AUD to -641,990.00 AUD, representing a -13.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Adherium since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Adherium historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Adherium

All Key Metrics — Adherium